UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating
ACADIA Pharmaceuticals (ACAD) has an average rating of outperform and price targets ranging from $13 to $39, according to analysts polled by Capital IQ. Price: 16.97, Change: -0.14, Percent Change: -0
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shareholders Have Endured a 37% Loss From Investing in the Stock Five Years Ago
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
ACADIA Pharmaceuticals (NASDAQ:ACAD) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares sinc
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock
Acadia Pharmaceuticals Presents New DAYBUE Clinical Data At The 2024 American Academy Of Neurology Annual Meeting
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that two oral presentations featuring DAYBUE (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (A
Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
26 analysts have expressed a variety of opinions on ACADIA Pharmaceuticals (NASDAQ:ACAD) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table provides
Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $37 Price Target
Cantor Fitzgerald analyst Charles Duncan reiterates ACADIA Pharmaceuticals with a Overweight and maintains $37 price target.
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
Taysha Draws Bullish View at Piper Sandler on Lead Asset
Rett Syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven res
Analysts' Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)
Needham: Reiterated ACADIA Pharmaceuticals (ACAD.US) rating, adjusted from buy to buy rating, target price $32.00.
Needham: Reiterated ACADIA Pharmaceuticals (ACAD.US) rating, adjusted from buy to buy rating, target price $32.00.
Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $32 Price Target
Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $32 price target.
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, A
Acadia Pharmaceuticals Insider Sold Shares Worth $317,081, According to a Recent SEC Filing
Stephen Davis, Director, CEO, on March 27, 2024, sold 17,714 shares in Acadia Pharmaceuticals (ACAD) for $317,081. Following the Form 4 filing with the SEC, Davis has control over a total of 118,842 s
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares
No Data